Gianvi is a combined oral contraceptive containing ethinyl estradiol and drospirenone. In a therapeutic dose, drospirenone also has antiandrogenic and weak anti-aldosterone properties. It is deprived of any estrogenic, glucocorticoid and antiglucocorticoid activity. It, in its turn, provides drospirenone with a pharmacological profile, similar to natural progesterone.
Indications for use
- Pregnancy prevention;
- Severe form of premenstrual syndrome.
Mechanism of action
Drospirenone has antiandrogenic properties due to the replacement of exogenous and endogenous androgens at specific receptors. It provides a therapeutic activity in inflammatory forms of vulgar acne. It also magnifies the number of high-density lipoproteins in plasma.
It arrests the release of the follicle-stimulating hormone and luteinizing hormone of the pituitary gland, interrupting the process of maturation of the egg. In such a way it excludes ovulation, imitating the physiological hormonal cycle. Suppressing the secretion of their own sex hormones, this substance excludes all the undesirable effects associated with the hyperfunction of estrogens and progestins: menstrual disorders, hyperplastic endometrial processes, fibrocystic changes in the mammary glands, ovulatory syndrome and premenstrual tension syndrome.
Mode of application and dosage
Daily, at about the same time, with a small amount of water, according to recommendations given on the package. The course lasts for 28 days. Gianvi dosage is 1 tablet per day. The menstruation usually starts on the 2nd-3rd day after the beginning of taking the placebo tablets and does not necessarily end at the beginning of the next package.
- Tumors of the mammary glands;
- Endometrial and ovarian cancer;
- Acute diseases and liver tumors;
- Intracranial hypertension (including history);
- Thrombophlebitis and thromboembolism in history;
- Undiagnosed bleeding from genital organs and urinary tract;
- Diabetes mellitus complicated by angiopathy;
- Ischemic heart disease;
- Pregnancy and lactation;
- Age under 18 years;
- Individual intolerance.
The most frequently reported side effects to include nausea and pain in the mammary glands. They were found in more than 6% of women who use Gianvi.
Severe adverse reactions include arterial and venous thromboembolism.
The following are adverse reactions with a very rare incidence or with delayed symptoms that are prone to be associated with taking medications from the group of combined oral contraceptives.
- the frequency of diagnosing breast cancer in women taking combined oral contraceptives is slightly increased. Due to the fact that breast cancer is rare in women under 40 years, an increase in the number of breast cancer diagnoses in women taking combined oral contraceptives is insignificant in relation to the total risk of the disease.
- liver tumors (benign and malignant).
- erythema nodosum;
- increased blood pressure;
- state, developing or worsening while taking combined oral contraceptives, but their relationship with the administration of the drug has not been proved (jaundice and/or pruritus associated with cholestasis, the formation of gallstones; porphyria; systemic lupus erythematosus; haemolytic-uraemic syndrome; Sydenham’s chorea herpes, hearing loss associated with otosclerosis);
- hereditary angioedema (estrogen may cause or aggravate its symptoms);
- impaired liver function;
- impaired glucose tolerance or influence on insulin resistance;
- crohn’s disease, ulcerative colitis;
- hypersensitivity (including symptoms such as rash, hives).
The interaction between Gianvi and other drugs may become a result of acyclic bleeding and/or low level of contraception.
The mechanism of interaction with hydantoin, barbiturates, primidone, carbamazepine and rifampicin; oxcarbazepine, topiramate, felbamate, ritonavir, griseofulvin, and St. John’s wort preparations is based on the ability of these active substances to induce microsomal liver enzymes. The maximum induction of microsomal liver enzymes is not achieved within 2-3 weeks, but after this is maintained for a minimum of 4 weeks after discontinuation of drug therapy.
The inefficiency of contraception was also noted when taking antibiotics, for example, ampicillin and tetracycline. The mechanism of this phenomenon is unclear. Women with short-term treatment (up to 1 week) of any of the above groups of drugs or mono drugs should temporarily use, in addition to combined oral contraceptives, barrier methods of contraception.
Women receiving rifampicin therapy, in addition to taking combined oral contraceptives, should use the barrier method of contraception and continue using it within 28 days after cessation of rifampicin treatment. If the application of concomitant drugs lasts longer than the end of the active tablets in the package, the intake of inactive tablets should be discontinued and immediately take drospirenone + ethinylestradiol tablets from the following package.
What if I miss a dose?
If you miss the active pill within the first 7 days you need to get the pill at the moment you observe this fact. If the number of days is greater, you are welcome to use additional methods of contraception. In any case, it is better to consult your doctor if you break doctor’s recommendations.
Gianvi and pregnancy
Gianvi is not intended for application during pregnancy and lactating period. It may provide a negative effect on the fetus development and breast milk.